Treatment Failure with Direct Antiviral Agents in Patients with Hepatitis C Virus Genotype 1 Infection at the Veteran Affairs Caribbean Healthcare System in San Juan, Puerto Rico.

CONCLUSION: Despite DAA effectiveness, phase III clinical trials with new IFN-free DAA-based therapies have a 5-7% treatment failure rates. Real-life data has showed that <15% of patients fail to achieve SVR in the most difficult to cure groups such as those with cirrhosis or subtype 1a. These findings are comparable with our current study. PMID: 31935314 [PubMed - in process]
Source: Puerto Rico Health Sciences Journal - Category: International Medicine & Public Health Tags: P R Health Sci J Source Type: research